Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 801–848 of 848
Caractérisation transcriptomique des cellules lymphoïdes innées
Crinier, A. (2020) · theses.fr (ABES) · doi:10.70675/850e38aazc227z4187z9c41z07c47cac00d9
Conséquences de l'engagement de CD28H sur les cellules "Natural Killer" humaines
Duplouye, P. (2020) · theses.fr (ABES) · doi:10.70675/ebac822ez44aaz4a68zbd6az7ecfb4157aa2
Vermeulen, O. (2021) · theses.fr (ABES) · doi:10.70675/277aa48cz7ec5z4c99z9fe9z34e8ea73f6b5
Pouxvielh, K. (2024) · theses.fr (ABES) · doi:10.70675/78db399bzce6az4d34z9634zfbe1e4580685
Mavouna, S. (2024) · theses.fr (ABES) · doi:10.70675/c882fe4fz5a26z4f88za6d9z814d62bb8385
Étude de la fonction de la DNASE1L3 en contexte auto-immun et anti-tumoral
Santa, P. (2024) · theses.fr (ABES) · doi:10.70675/2af1f0cfz45caz418azb93ez88367c4a54c8
Mapping the immune microenvironment of non-small cell lung cancer
Ge, X., Cai, M., Nie, J., Wang, L., Li, Y., Hu, Y., Meng, J., Liu, H., Geng, L., 花宝金, et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105335
E-cadherin expression promotes tumor growth via KLRG1-dependent pathways
Myers, J. A., Jordon, A. R. D., Borys, S. M., Dinh, K., & Brossay, L. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag046
“35,36 However, for the B16-F10 E-cad group, Rag1 − / − mice exhibited significantly more rapid tumor growth, revealing that an intact adaptive immune sys-tem is required for control of B16-F10 melanoma when E-cadherin is expressed (Fig.”
Natural Killer Cell‐Based Immunotherapy in HCC
Che, L., Xie, X., Yang, X., Zhu, S., & Zhou, Y. (2026) · Immunology · doi:10.1111/imm.70141
Chen, Y., Farooq, M. A., Hui, X., Huang, Y., Hu, Y., Xue, M., Ajmal, I., Ren, Y., Ji, Y., Wang, C., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08267-y
“…it was also shown that although the upregulation of inhibitory receptors on NK cell surfaces is a key event during depletion, the expression of immune checkpoints alone does not confirm that NK cells are depleted, as these molecules are also upregulated during the process of NK activation [44].”
Lui, M., Makinson, O., Walsh, M. L., Matthews, T. J., Woulfe, J., Ardolino, M., & Lorimer, I. A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724869
“Friebel et al. showed that a pattern of high microglia/macrophage percentage and low T cell percentage is a feature of glioblastoma, with brain metastases showing the opposite (22).”
InfluentialSelf-citationZhang, Z. L., Wu, Q., Chen, J., Zhao, Z. L., Cheng, Z., Jin, Y., Wu, C., & Yang, Z. Y. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005014
Nakatsuru, T., Yamashita, H., Mashima, C., Zhang, G., Saitô, H., Minamide, T., Nagaoka, K. H., Kamata, R., Sakai, S. A., Yamamoto, G., et al. (2026) · Cancer Science · doi:10.1111/cas.70381 · Cited by 1
Yuan, M., Yang, H., Wu, R., Hao, M., Chu, X., Deng, C., & Luo, K. Q. (2026) · Advanced Science · doi:10.1002/advs.75655
The Supporting Role of Natural Products as Effective Adjuvants in Cancer Immunotherapy
Liu, B., Huang, Y., Deng, J., Mao, Z., Bai, X., Ma, L., & Wang, J. (2026) · eFood · doi:10.1002/efd2.70171
Shukshin, A. A., Rubinstein, A., Головкин, А. С., Моисеева, О. М., & Kudryavtsev, I. V. (2026) · Medical academic journal · doi:10.17816/maj641690
Yadav, P., Chaudhary, P., Chaudhary, A., Sargam, S., & Manna, P. P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189635
Xiao, S., Wu, S., Shao, X., Chao, M., Huang, Q., Ke, C., Chen, J., Li, G., & Ye, L. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04387-z
“In addition, iron metabolism has been implicated in chemotherapy sensitivity and ferroptosis-based therapeutic strategies [27, 28, 31], raising the possibility that FTMT expression could inform treatment vulnerability in specific NSCLC contexts.”
Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential
Pommier, A., & Cancelas, J. A. (2026) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000939 · Cited by 1
Gao, H., Lei, Z., Wang, L., Li, Y., Chen, Z., & Wang, G. (2026) · Discover Oncology · doi:10.1007/s12672-026-05436-9
Berciano‐Guerrero, M., Pérez-Ruiz, E., Soria, A., Martínez, J. M., de Miguel, P. A., Muñoz‐Couselo, E., Bellido, L., Castro, R. L., Espinosa, E., Sanz, L. G., et al. (2026) · Cancer · doi:10.1002/cncr.70497
Huber, D., von Strachwitz, F., Hofmann, L., Pietrowska, M., Gawin, M., Chiang, D. M., Guder, C., Lotfi, R., Kishida, S., Pfaffl, M. W., et al. (2026) · Cancers · doi:10.3390/cancers18142219
“In HNSCCs, TAMs were shown to produce increased levels of EGF, promoting tumor growth [9], and to contribute to immunosuppression, for example, by PD-L1 expression, which inhibits T cell functions and induces apoptosis in natural killer cells [10,11].”
Zhu, Y., Shen, Y., Tang, W., Zheng, Z., Chen, S., Huang, Y.-H., Fu, D., Cheng, S., Xu, P. P., Wang, L., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02724-4
“PD-L1 on lymphoma cells engages PD-1 on NK cells, suppressing their cytotoxic activity in vivo [14].”
Mao, S., Fang, Y., Gao, J., Chen, J., Guan, Z., Zhao, X., Wu, J., Wu, X., Zhu, G., Zhang, X., et al. (2026) · 癌症:英文版 · doi:10.34133/cancomm.0043
“Metabolic reprogramming, such as enhanced glycolysis, fuels tumor growth and generates oncometabolites such as lactate, which can epigenetically suppress immune responses [ 19 , 20 ].”
Ruan, Z.-H., Zhang, S.-B., Zhang, Y.-Y., Chen, Z.-S., Zhang, H.-Q., Xu, Z.-H., Luo, T., Xiang, P., Fang, B.-J., & He, S. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01614-8
Myeloid-derived suppressor cells: A promising target for anticancer immunotherapy
Sharma, V., Bansal, S., & Aggarwal, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27731-3.00015-2
Poggi, A., Bruno, V., Spirito, A. D., Mortara, L., & Baci, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1784443
“Nevertheless, selected preclinical and translational studies indicate that PD-1/PD-L1 blockade can affect NK-cell function and may contribute to the ef fi cacy of ICB in some models (200 – 202).”
Sun, S., Fang, Y., Hao, H., Yu, J., Zhou, Y., Wen, S., Li, Y., Wang, T., Yu, M., & Wu, M. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124546
Franco, F. D., Greppi, M., Obino, V., Rebaudi, F., Goda, R., Caffa, I., Bozzo, M., Melaiu, O., Munari, E., Vellone, V. G., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1924522
Shi, J., ye, X., Chen, L., Wang, J., shen, H., Tian, T., Miao, Y., Wang, S., Lin, Q., Sun, Z., et al. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108300
劉玲玲 (2026) · Institutional Repositories DataBase (IRDB) · doi:10.14989/doctor.k26592
Feng, Y., Li, Q., Liu, Y., Liu, F., Luo, W., Song, Q., Zeng, Y., Bi, J., Zhang, G., & Li, Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.046
Kang, D.-W., Patel, D., Field, C. J., Boulé, N. G., Fairey, A., Schadler, K., & Courneya, K. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1923463
“Mechanisms of immune exclusion, including tumor and myeloid PD-L1 expression, which engages PD-1 on cytotoxic T and NK cells to suppress their activation and in fi ltration, can limit the tumor relevance of peripheral immune changes (33, 34).”
Ying, L., Zhou, S., Ma, X., & Xiang, X. (2026) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2026.2729441
Kim, D., Park, J., Kang, M.-S., & Jung, H.-W. (2026) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/xkbvg5btyx
Xing, S., 张佳宇, Wang, S., Hao, Y., Huang, D., Hao, M., Bao, W., Qu, X., Chi, Y., & Li, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1923822
Yu, Y., Liu, Y., Zhang, X., Yang, W., Hou, S., Yu, W., Zhang, F., Yu, B., Hu, Z., Wu, Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015873
“42 43 Particularly, the higher fraction of MAIT-derived cfRNA aligns with previous reports linking activated MAIT infiltration to superior anti- PD-1 responses in NSCLC. 44 Furthermore, the increased monocyte-derived cfRNA in the ITGB3-low group may represent an enhanced reservoir of plastic…”
Sholarin, A. M. (2026) · UND Scholarly Commons (University of North Dakota)
Zhang, D., Li, S.-H., Zhang, W.-H., Weng, J., Li, Z.-H., & Bai, K. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.126418
Shen, Y., Ye, X., Shen, S., & Lv, F. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127580
Ren, T., Yu, S., Jiang, X., Wen, J., Yan, C., Du, D., Tang, J., Peng, L., 吴三纲, Dai, C., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.324936
Chen, M., Lin, M., Zhu, J., Liu, K., Shu, G., Tong, Z., Zhou, M., Fu, L., Yang, T., Pan, Y., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199525
Self-citationNatural killer cell inflammatory circuits in antitumor immunity
Huntington, N. D., Meng, X., Chopin, M., & Delconte, R. B. (2026) · Nature Cancer · doi:10.1038/s43018-026-01276-2
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.